Skip to main content

Open Access Paediatric formulations for the treatment of drug resistant TB: closing the gaps

This article is Open Access under the terms of the Creative Commons CC BY licence.

No Abstract

Document Type: Editorial

Affiliations: 1: University of Sydney, Faculty of Medicine and Health, School of Pharmacy, Sydney, NSW, Australia, Westmead Hospital, Sydney, NSW, Australia, Sydney Institute for Infectious Diseases, University of Sydney, Sydney, NSW, Australia 2: Sydney Institute for Infectious Diseases, University of Sydney, Sydney, NSW, Australia, Children´s Hospital Westmead, Sydney, NSW, Australia 3: Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, The Netherlands, Department of Pharmaceutical Analysis, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands

Publication date: December 1, 2022

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease (IJTLD) is for clinical research and epidemiological studies on lung health, including articles on TB, TB-HIV and respiratory diseases such as COVID-19, asthma, COPD, child lung health and the hazards of tobacco and air pollution. Individuals and institutes can subscribe to the IJTLD online or in print – simply email us at [email protected] for details.

    The IJTLD is dedicated to understanding lung disease and to the dissemination of knowledge leading to better lung health. To allow us to share scientific research as rapidly as possible, the IJTLD is fast-tracking the publication of certain articles as preprints prior to their publication. Read fast-track articles.

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content